We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 688

Consumer Products Alert - June - August 2018
  • CMS
  • Global
  • September 18 2018

The French Competition Authority has initiated proceedings to formally investigate new purchasing alliances between several leading French food


CAFC Explains PTAB Burden Shift for Claimed Ranges
  • Ropes & Gray LLP
  • USA
  • September 17 2018

Since the Federal Circuit's decision in Magnum Oil, the Patent Trial & Appeal Board (PTAB) has been mindful that the ultimate burden of persuasion


Merger control investigation in Spain
  • Ernst & Young
  • Spain, Global
  • September 7 2018

What are the potential outcomes of a merger control investigation in Spain


Merger control triggers and thresholds in Spain
  • Ernst & Young
  • Spain, Global
  • September 7 2018

A structured guide to merger control triggers and thresholds in Spain


Reliance on Inherently Disclosed Embodiments in Prior Art is Dangerous
  • Haynes and Boone LLP
  • USA
  • August 28 2018

Prior art disclosures, and particularly non-patent literature, can be relied on for more than what they explicitly disclose. For example, many prior


Celltrion’s and Hospira’s Production of Infliximab Biosimilars Does Not Infringe Remicide-Related Patent
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • August 20 2018

In a 104-page ruling, U.S. District Judge Mark L. Wolf granted summary judgment in favor of Celltrion and Hospira, finding that a doctrine of


New Obligations for Registrants Arising Out of Proposed Amendments to NI 31-103
  • Fasken
  • Canada
  • August 14 2018

On June 21, 2018, the Canadian Securities Administrators ("CSA") published the proposed amendments to National Instrument 31-103 Registration


Federal Circuit Splits Hairs in Hair Removal Product Interference Proceeding
  • Marshall Gerstein & Borun LLP
  • USA
  • August 7 2018

In General Hospital Corp. v. Sienna Biopharmaceuticals, Inc., Case No. 2017-1012 (Fed. Cir. May 4, 2018), the Federal Circuit affirmed the PTAB’s


USPTO Says Overlapping Range In Prior Art Insufficient to Invalidate Method of Treatment Patent
  • Dechert LLP
  • USA
  • April 13 2018

Pharmaceutical patents frequently claim treatment methods that utilize a range of amounts or concentrations for the active ingredient or excipients


AMCU adopted the recommendations on assessment of non-horizontal concentrations
  • Dentons
  • Ukraine
  • April 5 2018

Recently, the Antimonopoly Committee of Ukraine (the AMC) adopted the Recommendations on Procedure for Applying of Part 1 of Article 25 of the Law of